Sandoz Inc. and its marketing partner, RareGen LLC, recently presented their case to a panel from the Third Circuit, requesting the reinstatement of the full $137.2 million in breach of contract damages originally awarded against United Therapeutics Corp. They argued that the decision by the lower court to reduce this amount unfairly benefited United Therapeutics. This legal battle stems from a dispute over a marketing and distribution agreement regarding the drug Remodulin, used to treat pulmonary arterial hypertension.
The initial jury verdict was delivered after Sandoz and RareGen accused United Therapeutics of not honoring the exclusivity provisions in their contract. According to Law360, the lower court later halved the damages, citing excessive calculations that skewed the compensation. In response, Sandoz and RareGen contend that this reduction undermines the jury’s findings and the intent behind the contractual agreements.
In their appeal, Sandoz emphasized the significance of enforcing contract terms to uphold market stability and protect legitimate business interests. They cautioned that diminishing the awarded damages could set a detrimental precedent, negatively affecting how companies engage and solidify commercial relationships. Recent reports from the legal community underscore the importance of this case in clarifying the boundaries of contractual obligations and damage assessments.
United Therapeutics, on the other hand, has maintained that the damages were rightly reduced. Their defense hinges on the argument that the jury’s award did not accurately reflect the contract’s terms or the actual harm incurred. This longstanding litigation continues to capture the attention of legal professionals, many of whom are keenly observing how the appeals court will interpret the complex interplay of contract law and equitable compensation.
The Third Circuit’s decision in this case, expected in the coming months, could have notable implications not only for the parties involved but also for future commercial contract disputes in the pharmaceutical industry and beyond.